Increasing Cases Of Cushings Disease To Boost The Cushings Syndrome Market Growth
Cushings Syndrome Market, By Treatment Type (Surgery, Radiation Therapy, Drugs, Others), Diagnosis (Petrosal Sinus Sampling, Saliva Test, Urine and Blood Tests, Imaging Tests), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Size, Share, Outlook, and Opportunity Analysis, 2022 – 2030
The global Cushings Syndrome Market is estimated to be valued at US$ 333.80 million in 2021 and is expected to exhibit a CAGR of 9.44 % over the forecast period, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Cushings Syndrome is also known as hypercortisolism is a problem that leads too much cortisol to be prepared. It impacts the master and adrenal glands. It generally takes place in kids and can lead to the difficulties in development, obesity, and other prodromes. The most general problem of Cushings syndrome is an irregularity in the pituitary gland.
This is the gland that usually makes the hormone adrenocorticotropic hormone. If one have a pituitary cancer, one might require operation to detach it. One will also require to consume drugs to decrease the amount of cortisol levels in the body. The supplier might order imagery methods to monitor for cancer in the master or adrenal glands.
Competitive Landscape:
Key players involved in the growth of global Cushings Syndrome Market are Strongbridge Biopharma, CORCEPT THERAPEUTICS, Novartis and HRA Pharma.
Market Key Drivers:
Increasing cases of cushings disease is expected to boost the growth of global Cushings Syndrome for Market. For instance, as per UCLA, around 10 to 15 people per million suffer from cushings disease.
The expansion of the worldwide Somatropin Market is anticipated to be driven by the growing long-term effects of growth hormone treatment on children with growth hormone insufficiency.
Rising elderly population is projected to propel the growth of global Cushings Syndrome for Market. For instance, as per WHO, around 1 in 6 people would be 60 years or above across the globe by 2030.
Covid-19 Impact Analysis:
The Covid-19 outbreak has adversely affected the growth of global Cushings Syndrome for Market due to the imposition of strict lockdown. The surge in cases has led to the delay in the treatment of others disease. The pandemic has led to the disruption in expansion of healthcare infrastructure and interrupted the supply chain.
Key Takeaways:
The global Cushings Syndrome Market is anticipated to exhibit a CAGR of 9.44 % during the forecast period owing to the rising product approvals and launches. For instance, in March 2020, the U.S. FDA approved Isturisa oral medicines for adults living with Cushing's disease.
Among regions, North America, Europe and Asia Pacific are expected to witness robust growth in global Cushings Syndrome for Market due to rise in cushings syndrome, rising R&D, rising investment in infrastructure and increasing geriatric population. For instance, as per NORD, around 13 per million people suffered from cushings syndrome in U.S.
Comments
Post a Comment